Business Context and Reporting Period
Company: Biorestorative Therapies, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 30, 2019 (Earliest event reported)
Reporting Period Covered: Events occurring between October 7, 2019, and November 5, 2019.
Status: Emerging Growth Company.
Key Financial Metrics and Capital Activities
This filing details specific debt repayment, debt-for-equity swaps, and new debt issuance rather than standard operating financial metrics (revenue, profit, cash flow).
- Debt Repayment: Repaid $1,384,038 in outstanding promissory notes (inclusive of accrued interest).
- Debt-for-Equity Conversion: Issued 1,482,839 shares of common stock to settle $75,501 of outstanding indebtedness (inclusive of accrued interest).
- New Debt Issuance: Issued convertible promissory notes with a principal amount of $210,750.
- Cash Proceeds: Received $195,000 in cash from the new convertible notes.
- Interest Rate: New notes bear interest at 12% per annum.
- Maturity Dates: Range from May 2020 to October 2020.
Material Changes and Transaction Details
The filing reports significant changes in the company's capital structure through the following transactions:
- Reduction of Liabilities: Significant reduction in debt load via cash repayment ($1.38M) and equity conversion ($75.5k).
- Dilution: Issuance of approximately 1.48 million shares of common stock to extinguish debt.
- Convertible Note Terms:
- $89,250 principal convertible at $0.25/share for six months, then 58% of fair value.
- $50,000 principal immediately convertible at ~60% of fair value.
- $71,500 principal convertible at the lesser of $0.15/share or 58% of fair value after six months.
Guidance, Risks, and Unusual Items
Regulatory Exemptions: The company relied on Section 4(a)(2) and Section 3(a)(9) of the Securities Act of 1933 for these transactions, asserting no public offering occurred and no general solicitation was used.
Investor Status: Management reasonably believes all investors are accredited.
Information Access: Investors were provided access to the 2018 10-K, 2019 10-Qs, and prior 8-K filings.
Guidance: The filing text does not provide forward-looking guidance, revenue outlook, or management commentary on future operations beyond the transaction terms.
Key Facts for Investor Verification
- Verify the impact of the 1,482,839 new shares on total outstanding share count and potential dilution.
- Confirm the remaining debt balance after the $1.38M repayment and $75.5k conversion.
- Assess the liquidity impact of the $195,000 cash proceeds against the 12% interest obligation on the new notes.
- Review the conversion price triggers (specifically the 58% and 60% discounts to fair value) for potential future dilution.
- Check subsequent filings for the actual maturity dates and any further conversions of the new notes.